Scott Schobel

Dr. Schobel joins VIco from Roche, where he was group medical director and most recently clinical science leader of the Roche tominersen and gantenerumab clinical development programs. At Roche, he pioneered the development of clinical endpoints in HD research, co-chaired a task force that generated a new research-based disease staging framework for HD based on underlying biology, and clinically led the first ever huntingtin-lowering therapy Phase 3 program with tominersen. Prior to Roche, Dr. Schobel was an assistant professor of clinical psychiatry at Columbia University Medical Center focused on studying hippocampal dysfunction across neurological and psychiatric diseases using a cross-species neuroimaging approach. He was also medical director of Columbia University Medical Center’s Center of Prevention and Evaluation (COPE), a clinical service dedicated to the treatment and longitudinal study of teenagers and young adults at high risk for psychotic disorders.

Scott earned a B.A. in Japanese from the University of Minnesota, an M.D. from the University of North Carolina, and an M.S. from Columbia University.